The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
This annual session will provide DDW attendees the opportunity to hear opposing viewpoints from leading GI experts on the most challenging issues in clinical gastroenterology and hepatology, in a debate format…
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations…
The Cochrane Gut group supports the production of high quality and methodologically rigorous reviews for a portfolio that includes upper GI, IBD and functional bowel disease topics in adults and children…